tp53-epha-2-car-dc
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2023 (NCT05631886)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Ephrin type-A receptor 2Immunity, passive
EPHA2 immunity, passive
- Cellular tumor antigen p53Immunity, passive
TP53 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05631886 | Phase 1 | Jan 1, 2023 | People's Liberation Army of China, Zhejiang University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2023 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1